Abstracts tagged "Biologicals"

Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Di Wu¹, Jing Li¹, Dong Xu¹, Li Wang¹, Jianmin Fang², Dan Ross³ and Fengchun Zhang⁴, ¹Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, ²Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, ³RemeGen Co., San Diego, CA, ⁴Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
Abstract Number: L12 • ACR Convergence 2022
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
Remco Erkens¹, Rashmi Sinha², Alex Pickering³, Grant Schulert⁴, Alexei Grom⁴, Lars van der Veken¹, Hanneke van Deutekom¹, Jorg Calis¹, Jorg van Loosdregt⁵ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Systemic JIA Foundation, Cincinnati, OH, ³Systemic JIA Foundation, San Francisso, CA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
Abstract Number: 0197 • ACR Convergence 2022
Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars
Stephen Bender¹ and Suzanne Schrandt², ¹FACTORx, Cherry Hill, NJ, ²ExPPect, Arlington, VA
Background/Purpose: The goals of this project were two-fold: The primary goal was to provide clinicians who treat rheumatoid arthritis (RA) and inflammatory bowel disease (IBD)…
Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Christopher Bell¹, Bernie Rubin², Karen Worley³, Guillaume Germain⁴, François Laliberté⁴, Sean D. MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ³GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, ⁴Groupe d’analyse, Montréal, QC, Canada, ⁵Analysis Group Inc, Boston, MA
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
Abstract Number: 0429 • ACR Convergence 2022
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Mark Siderius¹, Suzanne Arends², Freke Wink³ and Anneke Spoorenberg², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In patients with ankylosing spondylitis (AS), TNF-α inhibitors influence the course of serum bone turnover markers (BTM), favoring an increase in mineralization during the…
Abstract Number: 0768 • ACR Convergence 2022
Reevaluating Clinical Outcomes of Patients on Combination Biologics
Ryan Mathew¹, Alexa Meara², ChienWei Chiang³, Komal Paradakar³, Ambra Burrell³ and Gabriel Kirsch³, ¹The Ohio State University Medical Center, Skokie, IL, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Biologic treatments such as monoclonal antibodies have become first line treatment for many autoimmune diseases and now monoclonal antibodies are being used to treated…
Abstract Number: 0879 • ACR Convergence 2022
Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
Angela Zimmer¹, Ariane Klein¹ and Gerd Horneff², ¹Asklepios, St. Augustin, Germany, ²Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Golimumab (GOL) is approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety and…
Abstract Number: 1039 • ACR Convergence 2022
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Guillaume LARID¹, Guy Baudens², Alexis DANDURAND¹, Pascal COQUERELLE³, Vincent Goeb⁴, Marie-Hélène Guyot⁵, Laurent Marguerie⁶, Frédéric MAURY⁷, Viellard Eric⁸, Eric Houvenagel⁹, Jean Hugues SALMON¹⁰, René-Marc Flipo¹¹ and elisabeth gervais¹, ¹CHU Poitiers, Poitiers, France, ²Private practice, Valenciennes, France, ³CH Béthune, Béthune, France, ⁴CHU Amiens, Amiens, France, ⁵Private practice, Roubaix, France, ⁶Institut Calot, Berck-Sur-Mer, France, ⁷Private practice, Béthune, France, ⁸Private practice, St. Malo, France, ⁹Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ¹⁰Reims University Hospital, Reims, France, ¹¹CHU Lille, Boulogne-Billancourt, France
Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].